Fig. 7
From: Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development
FSCN1 serves as a potential therapeutic target for human OA. IF staining of FSCN1 (green) and phalloidin (red) staining for F-actin structures (a), relative mRNA expression of chondrogenic and dedifferentiation genes (b), western blot analysis of FSCN1, DCN, Collagen type II and III, p-Smad1/5 and Smad1/5 (c), IF staining and quantification of Collagen II (green) and III (red) (d) in human chondrocytes treated with control or NP-G2-044 (10 μmol/L) for 24 h (n = 3). e SOFG staining and absorbance quantification in explant-cultured cartilage tissue from OA donors treated with control or NP-G2-044 (10 μmol/L) for 7 days (n = 4). f-h. IHC staining and quantification of MMP13 and MMP3 (f), IF staining and quantification of Collagen type II (green) and III (red) (g), p-Smad1/5 (green) and β-catenin (red) (h) in explant-cultured cartilage tissue from OA doners treated with control or NP-G2-044 (10 μmol/L) for 7 days (n = 4). Scale bars, 100 μm. All data are presented as means ± SEM. i Schematic diagram showing the role and mechanism of FSCN1 in the regulation of chondrocyte dedifferentiation and the pathogenesis of OA
